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sychosis is an illness of the brain in which
thoughts are disordered and reality distortions occur,
like hallucinations and delusions.
1-3 These symptoms
characteristically manifest themselves within different
diagnostic categories.The diagnoses in which psychosis
often occurs are schizophrenia, characterized by a life-
long mental psychotic condition, bipolar disorder, in
which primarily affect disturbance occurs (mania or
depression), and dementia, in which loss of cognitive
capacity can be confounded by paranoia and thought
disorder. Other conditions, like drug abuse, alcoholism,
Parkinson’s disease,and Huntington’s chorea,are asso-
ciated with psychotic symptoms,less frequently and usu-
ally in a transient fashion.
The treatment of psychotic symptoms is the same in all
diagnostic categories,namely administration of antipsy-
chotic drugs.
4 Not all the symptoms of each of these ill-
nesses can be treated by antipsychotic drugs alone, eg,
the cognitive dysfunction in schizophrenia is minimally
affected by haloperidol, wich has little effect on the
affective dysregulation in bipolar disorder.
5 However,
hallucinations, delusions, and thought disorder are
treated similarly across the diagnoses,although different
dose levels, schedules, and durations are used.Antipsy-
chotic drugs are characterized by the common mecha-
nism of action of blockade of dopamine receptors.There
exist first- and second-generation antipsychotic drugs.
The first-generation drugs are characterized by pre-
dominant dopaminergic blockade,while the second gen-
eration of antipsychotic drugs involve more prominently
dopaminergic and serotonergic blockade.Clinically,the
second-generation drugs have few or no parkinsonian
side effects. Consequently, the second generation of
drugs is now more widely used than the first, and likely
to take over the market for treatment of psychosis.
6 
The antipsychotic properties of these drugs were discov-
ered serendipitously in the early 1950s by Delay and
Deniker,who reported the selective antipsychotic action
of chlorpromazine.
7 After the mechanism of action was
identified as dopamine/aminergic receptor blockade,
8,9
many newer drugs were developed,selectively designed
to block dopamine and other receptors.
10These are now
referred to as the first-generation antipsychotics.These
drugs were all developed on the basis of dopamine recep-
Psychosis is a mental condition characterized by halluci-
nations, delusions, and thought disorder; it spans diag-
nostic entities that respond to similar therapeutic
approaches. Psychosis has no fully described tissue
pathology, as yet, but is still identified and assessed
symptomatically. The first generation of antipsychotic
drugs was developed in the middle of the 20th century.
The second generation of drugs arrived in the 1990s. This
new group of antipsychotic drugs has potent therapeu-
tic actions on the positive symptoms of psychosis with far
fewer side effects, especially motor effects. However,
each of the new drugs has its own characteristic clinical
and pharmacological features that affect individual
patient response. Understanding these individual drug
characteristics can promote optimal drug choice and use
in conditions of chronic psychosis.
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However, all have potent antidopaminergic actions and
hence show parkinsonism and often cardiovascular side
effects along with their primary antipsychotic actions.
The first second-generation antipsychotic was clozap-
ine.
11 This drug is an old drug, not a new one, and
although it has the serious side effect of agranulocytosis,
it has several positive clinical properties, like no motor
side effects and uniquely potent antipsychotic actions.
When these properties were documented by Kane et al
in 1988
11 in a multisite controlled study for registration in
the USA,these new drug effects became targets for drug
development,producing a second generation of antipsy-
chotic drugs. The second-generation drugs were devel-
oped and introduced in the 1990s. This new group of
antipsychotics have been more broadly tested and have
clear clinical advantages; they have thus been widely
used.The first generation of drugs is often represented by
haloperidol,but is actually composed of drugs with high
affinity (eg, haloperidol) and low affinity (eg, chlorpro-
mazine) at the dopamine D2 receptor. The low-affinity
drugs have cardiovascular side effects, and were there-
fore soon abandoned in favor of high-potency com-
pounds like haloperidol. Now, the second-generation
compounds are replacing haloperidol and its congeners
because of their lack of motor side effects.
12 It is only the
remaining economic advantages of the first-generation
drugs that still compel their use.While the second-gen-
eration drugs have the common advantage of low or no
motor side effects, they are neurochemically and phar-
macologically distinct from each other, and probably
have distinct clinical characteristics as well.
Chronic psychoses
The chronic psychoses are brain diseases where psychotic
symptoms present themselves as a significant part of the
illness picture and require treatment.Within each distinct
illness, psychosis may be a varying part of the symptom-
atic picture, with schizophrenia showing consistent and
prolonged psychosis and dementia showing more tran-
sient symptoms. However, whenever they present them-
selves, the symptom configurations require treatment
because of their intrusive and absorbing nature, and
because of their morbidity and even mortality.
Schizophrenia is a lifelong psychotic illness that is also
characterized by cognitive and affective dysfunctions;it
affects 1% of the population worldwide.The core of dis-
ease definition is psychosis.There exist many different
manifestations of schizophrenia with the predominant
symptoms being psychotic,cognitive,or affective (nega-
tive symptoms).
13,14This is an illness where most affected
persons do not return to any normal existence,even with
the available treatments.Only perhaps 10% of affected
persons return to normal health and less than 20%
return to work.New treatments are essential.It appears
as though the available drugs primarily target positive
psychotic symptoms, and not cognitive dysfunction or
negative symptoms.However,each and every treatment
approach is helpful.Persons with schizophrenia require
medication throughout their entire lives.About 20% of
them do not respond to antipsychotic medications at all
and are candidates for clozapine.
Bipolar illness has a lifetime prevalence of 1.3% to
1.6%,with a 10% to 20% mortality rate due to suicide.
15
Psychosis is prevalent, nearly ubiquitous, during manic
episodes, most often requiring antipsychotic treatment.
All the second-generation drugs are effective and have
far less motor side effects than haloperidol.The second-
generation drugs appear to have similar efficacies, but
different side effects, particularly weight gain.
16 Use of
antipsychotic treatments along with mood stabilizers for
the treatment of acute mania has become routine.
In dementia,psychosis and other severe behavioral dis-
turbances like agitation,wandering,self-mutilation,and
assaultiveness all occur.Antipsychotic treatments at very
low doses (relative to schizophrenia) have been used
successfully to treat these psychotic and behavioral
symptoms.
17 Whether the behavioral disturbances are
clinical manifestations of psychosis or based on another
cerebral physiology, they are mitigated with antipsy-
chotic drugs.While the first-generation drugs are effec-
tive even in small doses,they are accompanied by motor
side effects.Thus, the use of second-generation drugs is
clearly indicated and effective in the elderly demented
patient, and are accompanied by manageable side
effects.
Antipsychotic drugs: individual characteristics
Haloperidol
Haloperidol is the prototypical first-generation antipsy-
chotic.Until the 1990s,haloperidol was the most widely
used antipsychotic for the treatment of any psychosis.
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Its potent antipsychotic action along with little sedation,
despite its considerable motor side effects,has sustained
its worldwide use.Those same characteristics have rec-
ommended its ongoing use, along with its economic
advantage.
Receptor affinity and animal pharmacology
The pharmacology of haloperidol is extensively and well
documented because the drug is the usual comparator
compound in animal research and was also used, for a
time, in human experiments. Haloperidol has a high
affinity for the D2 family of dopamine receptors. It has
little D1 receptor affinity,but does possess modest affin-
ity for the α 1 adrenoceptor and serotonin (5-hydroxy-
tryptamine) receptor 5-HT2,
18 but the latter may not be
manifest at clinically relevant dose levels. Haloperidol
defined the animal pharmacological actions of an
antipsychotic drug: it inhibits conditioned avoidance
responding; it blocks apomorphine- and amphetamine-
induced motor behaviors; and it induces catalepsy in
animal preparations.
19 It elevates dopamine metabolites,
homovanillic acid (HVA) and dihydrophenylacetic acid
(DOPAC),in rat dorsal and ventral striatum with acute
administration; it stimulates Fos protein expression
throughout rat striatum and the limbic forebrain with
acute administration
20; and it causes depolarization
blockade in the A9 and the A10 groups of dopamine
neurons with subchronic administration.
21Also,chronic
treatment in the rat upregulates dopamine receptor
number throughout striatum, modifies γ -aminobutyric
acid GABAA receptor binding in substantia nigra and
alters GABAA receptor density in rat thalamus.
22 Since
many of these pharmacological characteristics are now
linked to the undesirable motor side effects of antipsy-
chotics, these are not characteristically targeted in drug
development today.
Efficacy in chronic psychoses
The antipsychotic efficacy of haloperidol in schizophre-
nia was established in comparative trials in the early
1960s.
10 However,it was not until recently that a placebo-
controlled trial with a range of doses was completed
with this drug.
23 In this schizophrenia trial,doses of 4,8,
and 16 mg/day were tested against placebo in a multi-
center efficacy trial. The results showed haloperidol to
be a highly effective antipsychotic drug in this dose
range and there was no relationship between drug dose
and clinical response across this dose range.This lack of
detection of a relationship between dose and clinical
response across a usual clinical dose range suggests the
lack of sensitivity of large multicenter drug trials.
Haloperidol was used in the treatment of acute mania
long before clinical trials verified its action in that psy-
chotic condition.It is effective in managing the psychosis
at doses used in schizophrenia. However, motor side
effects are problematic and clinical use has been largely
taken over by second-generation compounds.
Similarly,in dementia,haloperidol was previously used in
the treatment of psychosis long before clinical trials ver-
ified the efficacy or the drug dose.Efficacy was apparent,
even at very low drug doses, up to 4 mg/day. Overt psy-
chotic symptoms respond as well as aggressive/agitated
behaviors. However, the frequency and severity of the
motor side effects have limited drug use.
24 Moreover,the
very high incidence of drug-induced dyskinesias (40%
per year)
25 further drove clinicians from the use of this
drug. While behaviorally effective, motor side effects
have effectively limited drug use in this condition.
Recent in vivo human imaging analysis of regional drug
action with haloperidol shows that the drug affects neu-
ronal metabolism and/or regional cerebral blood flow
(rCBF) in the striatum, thalamus, middle frontal cortex,
and anterior cingulate cortex (ACC).
26 Within the ACC,
drug action does not correct the abnormal task-activated
rCBF patterns in schizophrenia, but it appears to more
closely “normalize”rCBF in the frontal cortex (Figure 1).
The rCBF pattern changes with haloperidol are consistent
with the clinical actions and side-effect profile of the drug
(Lahti et al,personal communication).
Drug side effects and human pharmacokinetics
Haloperidol produces significant parkinsonism and
akathisia in a large number of subjects even at very low
dose levels. In a controlled multicenter trial that evalu-
ated 4 to 16 mg/day dose levels, the motor side effects
were evident at the lowest dose, suggesting that motor
side effects are inevitable,even at very low clinical doses.
However, other side effects produced by many of the
first-generation antipsychotic drugs,like cardiovascular
effects, anticholinergic actions, and hematological
changes,are no particular problem with haloperidol.The
compound fails to alter the QT interval on electrocar-
diography (ECG), a measure of cardiac repolarization
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time. Little weight gain has been documented with
haloperidol. Haloperidol has only one minor metabo-
lite (reduced haloperidol) and both parent and metabo-
lite are easy to analyze.Haloperidol’s half-life in humans
is 12 to 22 h in a mixed population and 12.2±2.6 h in
“good” metabolizers. In our hands (N=10), the time to
maximum concentration (Tmax) is 5±2 h,its distribution
half-life is 1.3±0.03 h;peak plasma level after 10 mg oral
concentrate (Cmax) is 12.3±6.7 ng/mL and elimination
half-life is 21.7±20 h (unpublished data).Treatment stud-
ies from multiple laboratories indicate that drug con-
centrations of 4 to 16 ng/mL form the therapeutic range
for the drug.
27
Clozapine
Clozapine was first marketed in the early 1960s, but its
use was severely restricted due to the acute agranulocy-
tosis seen in Finland and the associated deaths. How-
ever,despite this,the early use of the drug suggested its
unique antipsychotic actions; these were demonstrated
in the 1988 study by Kane et al.
11 Since then,use in per-
sons with psychosis unresponsive to other drugs has
been strongly advocated and the clinical outcomes have
been broadly positive. In some countries, eg, China,
clozapine has been used as a first-line drug because of its
outstanding clinical actions.
28 The clinical actions of the
drug have an associated human physiology,which is con-
sistent with its unique actions (see below).
Receptor profile and animal pharmacology
Clozapine has a broad affinity for many central nervous
system (CNS) receptors. It has measurable affinity not
only for D1 and D2 dopamine receptor families (D1,D 2,
D3,and D4),but also for the serotonin (5-HT1A,5-HT2A,
5-HT2C,5-HT6,and 5-HT7) receptors.In addition,it has
significant affinity for the α 1 and α 2 adrenergic, cholin-
ergic, and histamine sites.
18 Although the affinity of
clozapine for these sites overall is low,clinical doses are
relatively high,giving clozapine a broad but low-affinity
blockade of many CNS receptors in the clinical situa-
tion. As predicted by this receptor profile, clozapine
blocks animal behaviors and neurochemical changes
induced by dopaminergic,serotonergic,cholinergic,and
noradrenergic agents.
29 In addition, clozapine has dis-
tinctive regional actions in animal brain:it activates c-fos
mRNA only in limbic cortex and not in the dorsal stria-
tum
20;moreover,it affects dopamine cell bodies by pro-
ducing depolarization blockade only in the A10 neu-
ronal group (mesolimbic) and not in the A9 group
(nigrostriatal).
21These data are consistent with the clin-
ical actions and the lack of motor side effects that are
characteristic of clozapine.
Efficacy in chronic psychoses
In schizophrenia, clozapine has been demonstrated to
have a unique and superior antipsychotic action. This
was first demonstrated in those 20% of severely ill schiz-
ophrenics who are treatment resistant, but has been
extended to all partially responsive persons with schizo-
phrenia. This is to say that 35% to 50% of treatment-
resistant patients treated with clozapine demonstrate a
response to the drug.
11This response is characterized by
a decrease in positive and negative symptoms and an
improvement in cognitive function. Moreover, the
response is greater than to any other first- or second-
generation antipsychotic.
In psychotic affective conditions, clozapine shows clear
efficacy. However, characteristically, treatment in nor-
mal mania is not extended; moreover, other antipsy-
chotics show efficacy, thus the “nonresponder” status is
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Figure 1. Statistical parametric map derived from 
15O-labeled water
positron emission tomography (PET) scans rendered onto three-
dimensional standard brain displayed in the frontal coronal view.
This map indicates the difference in regional cerebral blood flow
(rCBF) obtained when the same schizophrenic volunteers (SVs)
were scanned, first medication-free, and then again after treat-
ment with haloperidol during performance of a cognitive task.
During the task, the haloperidol-treated SVs show rCBF changes
in the frontal cortex, bilaterally, compared with when they are
medication-free. 285
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rarely reached.Weight gain is a greater problem in mood
disorders than in schizophrenia,possibly only because of
the intact self-perception of the patient group,and cloza-
pine is burdened with this side effect. Consequently,
clozapine is not recommended as a first-line drug in this
area.
Clozapine has also been effective in dementia with psy-
chosis.Although side effects are substantial,with agran-
ulocytosis being more frequent,improvement is roughly
“moderate to marked,” even at low doses (100-150
mg/day).However,anticholinergic side effects can limit
use. However, if an indication for clozapine is estab-
lished, it can be effective and safely used in the elderly
with psychotic and/or severe behavioral disorders, pro-
vided there is careful monitoring.
Clozapine is the recommended treatment in the levo-
dopa (L-DOPA)–induced psychosis of Parkinson’s dis-
ease, where it characteristically fails to worsen the
parkinsonian symptoms. Psychotic symptoms have
become more common today with the introduction of L-
DOPA treatment.Moreover,mild psychotic symptoms,
if left untreated,have a tendency to worsen.
30 Clozapine
is generally effective and well tolerated in psychotic
symptoms accompanying late-stage Parkinson’s disease,
including sleep, motor, and sensory disturbances, and is
a first-line treatment.
31
In vivo imaging studies with clozapine suggest a poten-
tial mechanism for the superior clinical antipsychotic
action, namely that in humans, clozapine has the same
focused and “normalizing” action on limbic cortical
function as the drug shows in animal model studies.First,
clozapine has a greater activating effect on neuronal
activity in the ACC and the middle frontal cortex than
do other antipsychotics (specifically haloperidol) (Figure
2A).However,clozapine also has a “normalizing”action
on the behavior of the ACC during performance of a
task that utilizes the ACC (Figure 2B).
Drug side effects and human pharmacokinetics
Clozapine has a multitude of serious as well as inciden-
tal side effects,all of which affect patient use.Given the
serious nature of the side effects, it is indeed surprising
that the drug is used at all,and the fact that it is,is a tes-
timony to its superior clinical efficacy.The drug was first
noted to produce agranulocytosis after several deaths
Figure 1. A. Coronal statistical parametric map derived from 
15O-labeled water positron emission tomography (PET) scans indicating the difference in
regional cerebral blood flow (rCBF) between clozapine-treated and haloperidol-treated schizophrenic volunteers (SVs). Clozapine has a greater
activation effect in the anterior cingulate cortex (ACC) compared with haloperidol. B. Individual rCBF changes in ACC activation during per-
formance of a cognitive task in drug-free (DF), haloperidol-treated (Hal), and clozapine-treated (Cloz) SVs. Values for the normal group (NV)
are provided for reference. Clozapine, but not haloperidol, shows a “normalizing” action on the activation of the ACC during performance
of a cognitive task compared with drug-free SVs. Colors are coded such that the same color always identifies the same volunteer.
B. A.occurred in a Finnish hospital in the 1960s.The action of
clozapine in suppressing granulocyte production in the
marrow was described and its incidence gradually tabu-
lated over time, now known to be 0.5% to 1% with a
mortality rate of 3% to 15%.Currently,clozapine use is
restricted in the USA to those psychotic persons who
fail to respond to other drugs. Its use is also accompa-
nied by required blood counts, most frequent (weekly)
in the first 6 months of treatment.In addition,clozapine
causes weight gain, hypotension, tachycardia, arrhyth-
mias,sialorrhea,sedation,and seizures in addition to the
putatively more serious agranulocytosis. In reality, it is
these “lesser” side effects that most often cause drug
discontinuation.However,clozapine fails to cause acute
or chronic motor side effects to any notable extent.
Clozapine has several major metabolites,at least two of
which have CNS activity,norclozapine and desmethyl-
oclozapine. Too little is known about the actions and
kinetics of clozapine and its metabolites.After a single
dose of clozapine (200 mg),Tmax is 3±1.5 h and Cmax is
386±249 ng/mL. Its elimination half-life is approxi-
mately 10.3±2.9 h and its mean half-life is 17.4±7.7 h.
Plasma concentrations are linear with dose.
Risperidone
Risperidone was designed on the basis of the clinical
observation that haloperidol combined with a pure
serotonin antagonist showed fewer motor side effects
than haloperidol alone.
32 Risperidone contains both
the antidopaminergic and the antiserotonergic com-
ponents of the two distinct test drugs.Risperidone was
the first drug rationally designed to affect both the
dopamine and the serotonin systems, where the anti-
serotonergic actions are more potent than the anti-
dopaminergic actions. Although clozapine possesses
these properties, it was not designed as such. In the
clinical development of risperidone,the advantages of
this kind of drug target were delineated and their clin-
ical end points developed.
Receptor profile and animal pharmacology
Risperidone has high affinity for the D2 dopamine recep-
tor family and for the 5-HT2A and 5-HT7 receptors. The
drug also has high affinity for the α 1 and α 2 adrenoceptors,
but moderate affinity for the 5-HT2C and histamine H1
receptors.
18 The major active metabolite of risperidone,
9-OH-risperidone, has the same affinity profile.Thus, the
drug has antidopaminergic and antiserotonergic charac-
teristics in animal models of drug action,with greater anti-
serotonergic than antidopaminergic actions. It entirely
lacks anticholinergic properties. Risperidone increases
dopamine turnover in frontal and olfactory cortex to a
greater extent than it does in striatum.
19 Moreover,risperi-
done only produces catalepsy in rats at high dose levels.
Consistent with these behavior actions is the tendency of
risperidone to only activate c-fos mRNA in the ventral,
not dorsal striatum.However,the drug produces depolar-
ization blockade in A9 as well as A10 dopamine neurons,
without the selectivity shown by clozapine. Preclinically,
the animal profile is mixed with respect to whether or not
motor side effects would be predicted in human use.
Efficacy in chronic psychoses
Risperidone was first tested in a multicenter, multidose,
international study in the psychosis of schizophrenia.
33
Data from this trial indicated that the drug was surely
antipsychotic and potently so,but that the best dose was
in the lower dose range, around 6 mg/day, which was
confirmed in further studies. Current drug use studies
suggest that the doses of risperidone currently pre-
scribed are biphasic, with one peak around 2 to 5
mg/day and another peak at doses above 8 mg/day.The
lower dose range is not associated with parkinsonism
and only low levels of akathisia, whereas the higher
dose range has haloperidol-like levels of motor side
effects. Early use with risperidone suggested that the
drug might have some positive effects on cognitive dys-
function in schizophrenia. In in vivo ligand studies in
humans, the occupancy of striatal dopamine receptors
remains below 70% within the low dose range, while
occupancy of cortical serotonin receptors is higher by
about 20%, in the range of 80% to 95%.
34 This is char-
acteristic of the second-generation antipsychotics and is
consistent with their animal pharmacology.
Risperidone was one of the first second-generation
antipsychotics with low motor side effects,especially at
low dose levels, to also have a good side-effect pro-
file. Hence, the drug was used extensively, and then
studied,in the psychosis of the elderly,then an area of
great medical need. In an early report,
35 risperidone
was found to be “safe and effective” for psychosis in
the elderly,with hypotension being a use-limiting side
effect.Later controlled trials confirmed and extended
Clinical research
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these early observations.
36 An extensive development
program has demonstrated the drug to be effective
and well tolerated in many fragile patients
37 at doses of
0.5 to 1.5 mg/day.
38 Risperidone is widely used in the
elderly when an antipsychotic is required;the low anti-
cholinergic characteristics are positive for the elderly.
Drug side effects and human pharmacokinetics
Risperidone is not free of motor side effects in its higher
doses (above 6 mg/day).Whereas at dose levels below 4
to 6 mg/day motor side effects are at placebo levels,at the
higher doses sometimes needed in treated individuals,
especially schizophrenic patients, parkinsonism and
akathisia occur and they can do so at the same intensity
as with haloperidol.However,because this is such a com-
mon, if not usual, side effect, treatments and compensa-
tions exist for it and its presence does not rule out risperi-
done use. In addition, risperidone causes some weight
gain; its potency in this area is less than several of the
other second-generation antipsychotics,for reasons that
remain obscure,but the effect is greater than haloperidol
and considerably less than clozapine. Risperidone not
only elevates plasma prolactin,but also causes galactor-
rhea, particularly in women; this has become a signifi-
cant side effect,even though its frequency is low.
With respect to pharmacokinetics,risperidone is metab-
olized by the CYP2D6 liver isoenzyme system to its pri-
mary metabolite, 9-OH-risperidone. This metabolite is
active, and retains all of the pharmacological character-
istics of the parent compound. Thus, in kinetic studies,
the levels of both risperidone and 9-OH-risperidone
need to be taken into account.After a single 1-mg dose
of risperidone,Tmax is 1 h for risperidone and 3 h for 9-
OH-risperidone. The half-life of risperidone is 3.6 h,
whereas that for 9-OH-risperidone is 22 h. Kinetics are
dose-proportional up to 10 mg.Because the excretion of
9-OH-risperidone is renally dependent, its kinetics are
relatively independent of the rate of liver metabolism
and its half-life remains 20 to 22 h. In renally impaired
individuals and in the elderly,metabolism and excretion
are reduced.
39
Olanzapine
Olanzapine is an antipsychotic with a broader receptor
profile than risperidone and was developed to mimic
the pharmacology of clozapine. Olanzapine affects the
dopamine D2 receptor, several serotonergic and nor-
adrenergic receptors,and selectively the muscarinic M1
cholinergic receptor. It has greater serotonergic than
dopaminergic binding across its whole clinical dose
range (not just the lower clinical dose range like risperi-
done) and causes placebo-level motor side effects at all
clinically effective doses. Other unanticipated side
effects with olanzapine (eg,weight gain) have tended to
dampen otherwise strong enthusiasm for the drug,espe-
cially in some psychotic diagnoses.
Receptor profile and animal pharmacology
Olanzapine was developed to have a receptor affinity
profile similar to clozapine. Hence olanzapine has a
broad profile,including blockade of the D1 and D2 fam-
ilies and potent blockade of the 5-HT2A,5-HT 2C,5-HT 6,
M1,H 1, and α 1 receptors.
40 It differs from clozapine
receptor profile in the overall level of affinity for the 5-
HT1A receptor (higher for clozapine), α 2 blockade
(higher for clozapine),and in the spectrum of activity at
the M1 to M4 receptors (more restricted for olanzap-
ine).These differences are relatively minor in the over-
all picture and, in many ways, it is surprising that olan-
zapine is not more similar to clozapine. However, this
drug was evaluated carefully prior to clinical develop-
ment and found to lack any effects of bone marrow
effects,and hence no agranulocytosis.
Olanzapine has both antidopaminergic and antiseroton-
ergic actions in animal models, but has a higher antisero-
tonergic potency, like the second-generation antipsy-
chotics. Olanzapine produces depolarization blockade in
the A10 but not in the A9 dopamine neurons,
41 like cloza-
pine, and fails to affect c-fos activity in the dorsal stria-
tum.
42 With chronic treatment, olanzapine causes mild
dopamine receptor upregulation in striatum in the rat,but
significantly less than haloperidol.Olanzapine fails to pro-
duce dystonias in neuroleptic-sensitized Cebus monkeys
43
and fails to produce vacuous chewing movements in
chronically treated rats,
44 both suggesting that olanzapine
will not produce tardive dyskinesias in humans.Moreover,
the clinical data are so far consistent with this.
Efficacy in chronic psychoses
Olanzapine has a potent antipsychotic action in schizo-
phrenia, bipolar disorder, and psychosis associated with
dementia. Olanzapine was the second drug approved forClinical research
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psychosis in psychotic disorders directly after risperidone.
The drug was studied in four large placebo-controlled trials
in schizophrenia.
45,46 Results from all studies were consistent
and reported significantly greater antipsychotic activity
than placebo on both positive and negative symptoms and
equivalent activity to haloperidol on positive symptoms.
These data suggested that olanzapine is better than
haloperidol on negative symptoms.However,whether this
outcome is an effect on primary or secondary symptoms
has been argued. Olanzapine has been compared with
chlorpromazine in treatment-resistant patients and been
found to be equivalent.
47Although other equivalence stud-
ies (rather than difference studies) have been done and
found supportive, the definitive study was negative. That
olanzapine might lack such a pivotal characteristic of cloza-
pine, despite its very close structure and pharmacology,
was surprising and has been puzzling for identifying the
critical mechanism for clozapine action in schizophrenia.
Olanzapine has been tested in randomized controlled,
multicenter,clinical trials in mania.The drug is effective
in treating mania and was the first of the second-genera-
tion compounds to receive an indication in this area.
48
Treatment was rather short in these trials (3 weeks),but,
when needed in clinical practice,often extends for longer,
eg, 6 months, but it is not characteristically chronically
administered in mania unlike in schizophrenia.
For the psychotic and behavioral symptoms that accom-
pany dementia, olanzapine has also undergone testing
in controlled multicenter trials.Doses in the lower range
(5-10 mg/day) were effective and well tolerated.
49 Side
effects included somnolence and gait disturbance,but no
measurable interference with cognitive function. Olan-
zapine is safe and effective for agitation and psychosis in
elderly demented persons.
Drug side effects and human pharmacokinetics
The motor side effects with olanzapine are remarkably
and significantly diminished from those appearing with
haloperidol.
45This result is consistent across all clinical
studies. Parkinsonism and akathisia are absent at rec-
ommended dose levels, though mild akathisia and a
low level of anticholinergic medication use can be
detected at higher dose levels. Other side effects with
olanzapine are generally mild, except for weight gain.
Mild somnolence and dizziness have been noted. The
weight gain is clear and appears to be cumulative over
time.Metabolic abnormalities of carbohydrate metab-
olism leading to diabetes have been reported. They
were initially thought to be secondary to the weight
gain,but are now suspected to be independent.No car-
diac effects, blood dyscrasias, serious liver toxicity, or
lasting prolactin elevations have been noted.
Olanzapine has two primary metabolites, 4-N-
desmethylolanzapine and 10-N-glucuronide olanzapine,
both of which seem to be behaviorally inactive.The par-
ent compound has weak affinity for several different
hepatic isoenzyme systems, including CYP2D6,
CYP1A2, CYP3A4, and CYP2C19. This suggests that
minimal drug–drug interactions occur with olanzapine,
because so many routes of degradation exist.The half-
life of olanzapine is long (31 h; range 21-54 h) and the
Tmax is 5 h. Gender influences drug metabolism, in that
females metabolize the drug more slowly and conse-
quently have higher plasma levels at fixed dose levels.
Quetiapine
Quetiapine was developed to mimic the receptor profile
and the pharmacology of clozapine. As such, it has very
weak affinity for both the dopamine and the serotonin
receptors and a broad profile at the other receptors;it still
has a higher serotonin than dopamine receptor affinity.
Early on, drug potency was questioned probably because
the recommended dose levels were not high enough.Side
effects appear to be mostly clozapine-like, except for the
agranulocytosis,which none of the new drugs displays.Nor
have any of the new drugs yet demonstrated unique
antipsychotic actions. Side effects are very low.
Receptor profile and animal pharmacology
Quetiapine has a very broad receptor affinity profile,
with significant but weak attraction to the D1 and D2
family of dopamine receptors,to the 5-HT1A,5-HT2A,5-
HT6, and 5-HT7 families of serotonin receptors, and to
the α 1 and α 2 noradrenergic and H1 receptors without
muscarinic affinity.
18 These affinities are low, but in the
range of those of clozapine. Quetiapine increases
dopamine metabolites in striatum with acute adminis-
tration, but fails to upregulate D2 dopamine receptors
with chronic treatment. The c-fos upregulation pattern
produced by quetiapine resembles clozapine.Quetiapine
blocks dopamine- and serotonin-induced animal behav-
iors in laboratory testing and fails to induce catalepsy at
clinically relevant doses.
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Efficacy in chronic psychoses
Quetiapine has a significantly greater antipsychotic
action than placebo according to several controlled trials
at doses of 150 to 750 mg/day.
51 Moreover,it has actions
equivalent to haloperidol and risperidone on positive
and negative symptoms.Several studies also document a
positive effect of quetiapine on cognitive dysfunction in
schizophrenia, especially attention and working mem-
ory.This effect will need to be documented as a distinct
action from the antipsychotic effects, and such studies
are now under way.
Quetiapine has been tested in mania,but not in multisite
controlled trials. Nonetheless, in open clinical use, que-
tiapine seems to have the usual antipsychotic action in
mania as reported for other agents.
52 Moreover,it is safe
and apparently effective in adolescent mania.
53 In the
area of behavioral disruption/agitation in dementia,que-
tiapine requires further study with systematic evalua-
tion. However, because other agents have been tested
and found effective in the psychosis and agitation of the
elderly with dementia, quetiapine has been similarly
applied. Open results indicate that the drug is effective
and well tolerated in elderly dementia and should be
further and rigorously tested.
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Drug side effects and human pharmacokinetics
Quetiapine has a benign side-effect profile. It fails to
induce motor side effects in excess of placebo. No
akathisia is apparent.Reported side effects include seda-
tion, somnolence, and headache. Mild weight gain does
occur,but at lower levels than with clozapine.The report
of cataracts in animals developing during drug treat-
ment have failed to show extension to humans, and
hence no cataract risk currently exists for humans and
slit-lamp examinations are not necessary.
The plasma half-life of quetiapine is approximately 6 h.
The kinetics are linear up to 600 mg. Drug clearance is
reduced in the elderly, and so lower doses should be
used in this population.
Ziprasidone
Ziprasidone is a drug designed to have a high ratio of
serotonin (5-HT2) to dopamine receptor affinity. In
addition,it has some unique properties,one of which is
to block serotonin and norepinephrine reuptake block-
ade; this is a rather potent action on the reuptake pro-
teins, though related advantages have not been ade-
quately explored as yet. Its approval by the Food and
Drug Administration (FDA) was delayed because the
drug was shown to produce QTc prolongation, consis-
tent with potential cardiac arrhythmias.Additional stud-
ies were required for ziprasidone to rule out added car-
diac risk. A large study has been carried out on the
effect of ziprasidone on QT duration. The results
showed a mild prolongation,but without any worsening
with a metabolic inhibitor. Overall safety of the drug
has been confirmed in a large data set.
Receptor profile and animal pharmacology
Ziprasidone has a high affinity for the D2 dopamine
receptor family,for all the serotonin receptor families,
for α 1,but not α 2,adrenoceptors,and for the 5-HT and
norepinephrine reuptake proteins. It has the highest
ratio of serotonin to dopamine affinity of any of the
second-generation antipsychotics.Moreover,it appears
to have agonist action at the 5-HT1A receptor (as does
clozapine), whereas it is an antagonist at all other
receptors.
Behaviorally, ziprasidone potently inhibits dopamine-
and serotonin-mediated behaviors. It inhibits condi-
tioned avoidance response in rats.It decreases sponta-
neous locomotor activity and causes catalepsy at very
high doses (probably no longer clinically relevant).
Efficacy in chronic psychoses
Ziprasidone is a highly effective antipsychotic drug in
the dose range of 80 to 160 mg/day compared with
placebo and with active comparators;its effects on pos-
itive and negative symptoms are equivalent to haloperi-
dol (R. O’Connor et al, personal communicaction)
Because of the unique receptor and reuptake-protein
binding profile, broader effects were postulated for
ziprasidone other than merely effects on psychosis.This
profile predicts antidepressant and possibly cognition-
enhancing characteristics. No extraordinary clinical
actions have yet been detected.However,these evalua-
tions are ongoing,and signal detection is low due to the
complex symptom picture and the confounding of cog-
nitive change with psychosis improvement. Therefore,
clinicians should expect clear indications for schizo-
phrenia subtypes to develop.Clinical research
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Studies of ziprasidone in mania and in psychotic/agitated
dementia are ongoing,but not yet published.Because all
of the other antipsychotics have efficacy in these psy-
chotic diagnoses,the probability is great that ziprasidone
will be found to be effective as well. Perhaps in non-
schizophrenic psychoses,it will be easier to demonstrate
a cognitive or affective action of ziprasidone.
Drug side effects and human pharmacokinetics
Ziprasidone has no dose-related motor side effects that
can be distinguished from placebo, and it produces no
weight gain even over time.The latter side-effect advan-
tage may be particularly important in persons with
abnormal glucose handling with other drugs. Some
akathisia has been noted.Other side effects are benign,
except for one. Ziprasidone prolongs the QT interval
on ECG by approximately 15 to 20 ms. This prolonga-
tion could be associated with torsades de pointes (a ven-
tricular arrhythmia).There was an exhaustive study car-
ried out to document the effect of ziprasidone on cardiac
parameters, particularly the QT duration, relative to
other antipsychotics and, repeated using metabolic
inhibitors.The composite QT prolongation characteris-
tics of the following drugs, thioridazine, ziprasidone,
risperidone, quetiapine, olanzapine, and haloperidol,
were 36,16,8,6,4,and -2 ms,respectively.
The study showed that,with a metabolic inhibitor,there
was no worsening of this QT prolongation with ziprasi-
done. Moreover, with a very large clinical database,
including several cases of overdose with QT monitor-
ing, showed no increased incidence of adverse events,
even all-cause mortality.The increases in QT length are
mild and no increase in overall mortality with drug use
has been shown. Consequently, despite the QT prolon-
gation, no adverse cardiac events have been linked to
ziprasidone. Thus, the drug has been approved by the
FDA with minimal restriction and is being successfully
marketed.Its freedom from weight gain as a side effect
and its potential for antidepressant actions due to its
reuptake protein blockade should be advantageous for
this antipsychotic.
Pipeline compounds and novel approaches
Many antipsychotic drugs remain in development.Some
are pharmacologically similar to current compounds,
being potent D2 dopamine and 5-HT2 serotonin receptor
antagonists.Despite pharmacological similarities,clinical
activity differences in efficacy and particularly in side-
effect profiles do become apparent with clinical use.
Consequently,there still exists room for new or second-
generation antipsychotic drug development.
However,drugs acting through novel mechanisms to pro-
duce a putative antipsychotic action are also being devel-
oped and tested.Aripiprazole (a partial dopamine agonist)
has been shown to have equivalent efficacy to other
antipsychotics and has a more benign side-effect profile
than D2blockers.Iloperidone and sertindole are being pre-
pared for regulatory review. OSU6162 and ACR-16 are
two chemical congeners of each other developed by Arvid
Carlsson and called dopaminergic “stabilizers” because
they reduce dopaminergic function when elevated and ele-
vate dopaminergic function in hypodopamine situations.
Moreover, in some categories (glutamatergic drugs,
nicotinic agonists, muscarinic-1 antagonists, and
metabotropic agents), glutamatergic antipsychotic drug
strategies are being subjected to evaluation first in ani-
mal models, and then in human studies. Clinicians look
forward to having novel antipsychotics potentially tar-
geted at disease pathophysiology.
Summary and conclusions
The state of therapeutic agents for psychosis is broad today
and rather full of opportunity for patients.Whereas there
was a long “dry”period in drug development for psychosis
throughout the whole of the 1980s, research and develop-
ment laboratories have turned their attention to entirely
more creative antipsychotic strategies.Suddenly,a wave of
new second-generation drugs were able to stand up to clin-
ical development and now clinicians have several at least
equally efficacious treatments with far fewer side effects.
Even now, new ideas and hypotheses exist for drug treat-
ment of chronic psychosis,promising a hopeful future.❏Treatments for chronic psychosis - Tamminga and Lahti Dialogues in Clinical Neuroscience - Vol 3 .No.4 .2001
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Tratamientos para las psicosis crónicas
La psicosis es una condición mental que se carac-
teriza por alucinaciones, delirios y trastornos del
pensamiento e incluye varios cuadros clínicos
que responden a estrategias terapéuticas simila-
res. Hasta la fecha la psicosis no tiene descrita
completamente una patología tisular; sin embar-
go, está bien identificada y evaluada sintomáti-
camente. La primera generación de fármacos
antipsicóticos fue desarrollada a mediados del
siglo XX. La segunda generación de fármacos
apareció en la década de los ’90. Este nuevo
grupo de fármacos antipsicóticos tiene acciones
terapéuticas potentes sobre los síntomas positi-
vos de la psicosis con bastantes menos efectos
secundarios, especialmente a nivel motor. Sin
embargo, cada uno de los nuevos fármacos tiene
sus propias características clínicas y farmacológi-
cas que afectan la respuesta individual de los
pacientes. La comprensión de estas característi-
cas individuales de los fármacos puede facilitar
una elección óptima de ellos y su utilización en
casos de psicosis crónicas.
Traitement de la psychose chronique
La psychose est une maladie psychique caractérisée
par la présence d’hallucinations, d’idées délirantes,
et de perturbations de la pensée. Le terme de psy-
chose recouvre toute une gamme d’entités dia-
gnostiques qui répondent à des approches théra-
peutiques similaires. Aucun stigmate organique n’a
pu être décrit de façon définitive pour cette mala-
die, dont le diagnostic et l’évaluation du degré de
sévérité reposent encore uniquement sur des cri-
tères symptomatiques. La première génération de
médicaments antipsychotiques a vu le jour vers le
milieu du XX
e siècle, suivie d’une seconde généra-
tion dans les années 90. Ce nouveau groupe de sub-
stances antipsychotiques est doté d’effets théra-
peutiques puissants vis-à-vis des symptômes positifs
de la psychose, tout en bénéficiant d'effets secon-
daires moins nombreux, en particulier en ce qui
concerne ceux relatifs à la motricité. Chacun de ces
nouveaux produits n’en possède pas moins ses par-
ticularités cliniques et pharmacologiques qui
influent sur la réponse individuelle des patients au
traitement. Une bonne connaissance de ces parti-
cularités permettra de déterminer de façon opti-
male quel médicament choisir et comment le pres-
crire dans le cadre de la psychose chronique.
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